Conversion to Monotherapy Study With Keppra XR for Partial Seizures
Conversion to Monotherapy Study With Keppra XR for Partial Seizures
The primary objective of this study is to assess the efficacy of two doses of Keppra XR
 compared with a historical control as the placebo, in the monotherapy treatment of partial
 onset seizures.
Inclusion Criteria:

 -  Male or female subjects 12 to 75 years of age.

 -  Subjects must have inadequately controlled partial onset epilepsy.

 -  Subjects must be experiencing 2 to 40 seizures per 4-week period while being
 maintained on one or two standard AED(s)

 Exclusion Criteria:

 -  A history of status epilepticus in the 6 months preceding randomization.

 -  Significant medical, psychiatric or neurological illness.

 -  Intake of benzodiazepines on more than an occasional basis

 -  History of previous treatment with levetiracetam or sensitivity to levetiracetam.